The clustered regularly interspaced short palindromic repeat (CRISPR)/Cas system is best known for its role in genomic editing. It has also demonstrated great potential in nucleic acid biosensing. However, the specificity limitation in CRISPR/Cas has created a hurdle for its advancement. More recently, nucleic acid aptamers known for their high affinity and specificity properties for their targets have been integrated into CRISPR/Cas systems. This review article gives a brief overview of the aptamer and CRISPR/Cas technology and provides an updated summary and discussion on how the two distinctive nucleic acid technologies are being integrated into modern diagnostic and therapeutic applications

Direct oral anticoagulants such as direct factor Xa inhibitors are now commonly prescribed to manage patients with blood clotting disorders. The main advantage of this class of medication is free of routine monitoring in non-complicated patients. However, the complex pharmacokinetic profiles of special populations can complicate the dosing regimen of the oral anticoagulants.

Direct oral anticoagulants such as direct factor Xa inhibitors are now commonly prescribed to manage patients with blood clotting disorders. The main advantage of this class of medication is free of routine monitoring in non-complicated patients. However, the complex pharmacokinetic profiles of special populations can complicate the dosing regimen of the oral anticoagulants.

Direct oral anticoagulants such as direct factor Xa inhibitors are now commonly prescribed to manage patients with blood clotting disorders. The main advantage of this class of medication is free of routine monitoring in non-complicated patients. However, the complex pharmacokinetic profiles of special populations can complicate the dosing regimen of the oral anticoagulants.